/
ERAS
$18.29+$2.28 (+14.24%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$5.0B
311M shares
52-week range
$1.24 – $24.28
74% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$0.86
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $829.0K | $2.6M | $3.7M | $0 | $3.1M |
| Gross profit | $0 | $0 | −$829.0K | −$2.6M | −$3.7M | $0 | −$3.1M |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $9.6M | $101.3M | $73.9M | $112.5M | $103.8M | $115.4M | $92.9M |
| Operating income | −$13.3M | −$109.3M | −$124.9M | −$247.4M | −$141.5M | −$179.6M | −$131.4M |
| EBITDA | −$13.0M | −$37.0M | −$121.9M | −$240.2M | −$121.3M | −$153.3M | −$121.4M |
| Net income | −$12.0M | −$101.7M | −$122.8M | −$242.8M | −$125.0M | −$161.7M | −$124.5M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.10 | -0.85 | -1.03 | -1.99 | -0.83 | -0.69 | -0.44 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8M | $-0.96 | $-1.01–$-0.93 | 8 |
| 2027 | $428571 | $-0.56 | $-0.70–$-0.50 | 8 |
| 2028 | $4M | $-0.66 | $-0.91–$-0.55 | 7 |
| 2029 | $44M | $-0.78 | $-0.78–$-0.78 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.10
Price
$18.29
Implied downside
-99%
Peer comparison
Erasca, Inc. Common Stock
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
www.erasca.com- Employees
- 103
- IPO / List date
- Jul 16, 2021
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds ERAS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,398,869 | $22.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ERAS yet.
